October 23, 2012
The recent performance of some big pharma stocks might have some investors thinking that the patent cliff is nothing to worry about. It's easy to understand how that sort of attitude could exist. Take the performance of a stock likeÂ Eli Lilly (NYSE: LLY ) as an example. Shares have risen some 35% in the past year despite the fact that two huge drugs come off patent next year.
In the following video, health care bureau chief Brenton Flynn runs through the situation, and outlines some recent news that could help the company offset these losses by taking share in the lucrative diabetes market.Â
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.